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Abstract The aim of the study was to evaluate CXCL4
levels in undifferentiated connective tissue disease at risk
for SSc (UCTD-SSc-risk) and confirm its increase and
investigate its prognostic value. Serum CXCL4 levels
were measured in 45 patients and 24 controls. CXCL4
was significantly higher in UCTD-SSc-risk patients than
in controls. It resulted higher in patients with a shorter
disease duration and in those lacking capillaroscopic
alterations. We confirm that CXCL4 levels are increased
in UCTD-risk-SSc patients. Further studies are needed to
investigate the role of CXCL4 assessment in UCTD-risk-
SSc.
Keywords Systemic sclerosis ! Undifferentiated
connective tissue disease
Introduction
Very early (or early) SSc is a condition characterized
by Raynaud’s phenomenon (RP) plus SSc marker
autoantibodies and/or distinct capillaroscopic alterations
[1, 2]. It carries a significant, but not absolute risk of
evolution into definite SSc [3, 4]. Because of this
prognostic evidence as well as to avoid any nosographic
confusion with early definite SSc or early diffuse SSc
[5–7], it should be properly referred to as undifferen-
tiated connective tissue disease (UCTD) at risk for SSc
(UCTD-SSc-risk) [8].
Van Bon et al. [9] recently reported increased platelet
factor 4 (CXCL4) levels in both the plasma and skin of
patients with systemic sclerosis (SSc) in whom they
resulted to be associated with distinct clinical features and
to predict a poorer prognosis. They also pointed out
increased values in patients with very early SSc, but did not
investigate any association between them.
The aim of this study is to confirm increased CXCL4
levels in patients with strictly defined UCTD-SSc-risk and
to evaluate whether this finding is associated with any
disease feature and/or is predictive of evolution into defi-
nite disease [3, 4].
Materials and methods
Forty-five patients with UCTD-SSc-risk consecutively
admitted from November 1st 2000 to December 31st 2013
were enrolled in the study after giving a written informed
consent.
Classification
UCTD-SSc-risk was diagnosed in patients with RP and
either SSc marker autoantibodies or distinct capillaro-
scopic alterations or both, who at admission neither sat-
isfied the 2013 ACR/EULAR criteria for SSc [10] nor
presented any manifestation indicative of SSc sine scle-
roderma [11].
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Assessment at admission
Patients underwent a detailed history, an accurate physical
examination, routine laboratory investigations, nailfold
capillaroscopy, autoantibodies detection and investigation
of preclinical organ involvement as already described [4].
Subsetting
Patients were subdivided into 3 subsets [12]: subset I
(patients with both SSc marker autoantibodies and capil-
laroscopic abnormalities), subset II (patients with only
marker autoantibodies, i.e., anti-centromere or anti-DNA
topoisomerase I or anti-RNA polymerase III or anti-Fib-
rillarin or anti-Th/To or anti-Pm-Scl), and subset III (pa-
tients with only capillaroscopic abnormalities, i.e.,
megacapillaries and/or avascular areas) (Table 1).
Serum marker quantification
To avoid any influence of platelet-derived chemokines [13],
we measured CXCL4 levels in the serum of 45 patients at
admission and in 24 osteoarthritis/fibromyalgia control sub-
jects matched for sex and age. Peripheral blood was obtained
at baseline by venipuncture. Serum was separated by cen-
trifugation at 1500g for 10 min, aliquoted and stored at
-20 "C. CXCL4 levels were measured by a suspension flu-
orescence-based immunoassay (Merk Millipore, Billerica,
MA, USA) using a Luminex 200 instrument (Luminex Cor-
poration, Austin, TX, USA). Serum samples were diluted
1:40,000, and final concentrations of CXCL4 were expressed
as ng/ml. No patient was under glucocorticoid and/or
immunosuppressive treatment at the time of blood drawing.
Follow-up
After enrollment, patients were re-evaluated at yearly
intervals, up to December 31, 2015, by history taking,
clinical examination, EKG, B-mode-echocardiography,
esophageal barium X-ray, lung function testing and lung
high-resolution tomography to assess whether and when
each of them satisfied the ACR/EULAR classification cri-
teria disease score C9) [10] and/or criteria for SSc sine
scleroderma [11].
Statistical analysis
We used the SPSS for Windows software (version 16.0) for
statistical analysis. Categorical data were analyzed by Chi-
square test. Continuous data were compared by the Mann–
Whitney U test. A p value\0.05 was considered signifi-
cant. Risk was assessed by assessing hazard ratios in uni-
variate and step-wise regression analysis.
Informed consent
Informed consent was obtained from all individual partic-
ipants included in the study.
The study was approved by the Ethics Committee.
Results
Serum CXCL4 was significantly higher in the 45 UCTD-
SSc-risk patients [median 4.84 ng/ml; interquartile range
(1.83–10.82)] than in controls [median 1.43 ng/ml;
interquartile range (0.21–2.70), p = 0.0001]. In detail,
serum CXCL4 resulted to be significantly higher in 28
subset I [median 4.74 ng/ml; interquartile range
(1.67–10.18), p = 0.0012] and in 13 subset II patients
[median 7.0 ng/ml; interquartile range (2.9–16.8),
p = 0.0002] than in controls, while no difference was
detected between 4 subset III patients [median 2.32 ng/ml;
interquartile range (1.7–3.3)] and the 24 controls. More-
over, serum CXCL4 levels were almost significantly higher
in 13 subset II patients (i.e., those lacking microcirculatory
abnormalities as detected by nailfold videocapillaroscopy)
than in 32 subset I ? III patients (p = 0.07).
No other association was detected between CXCL4
levels and either disease duration or autoantibody speci-
ficity or presence of any (esophageal and/or cardiac and/or
lung) preclinical internal organ involvement.
At December 31, 2015, 4 patients had been lost to fol-
low-up, 1 patient died (pulmonary embolism). The
remaining 40 had been monitored for 6–101.4 months
(median 25.4 months; interquartile range 12.4–47.4; 19.04
patient/years follow-up). At the study closure, 26/40
(65 %) patients had evolved into definite SSc (at
6–101.4 months from enrollment into the study; median
24.35 months interquartile range 8–41.5). Of these, 9 only
had CXCL4 values at baseline [95th percentile of the
values recorded in controls (8.30 ng/ml). Nevertheless, 2
out of the 3 patients with the highest values (Fig. 1) had
evolved into definite SSc.
Figure 2 shows the receiver operator curve devoted to
identify the performance of baseline serum CXCL4 in
predicting the evolution into definite SSc. A baseline
CXCL4 value[8.3 ng/ml was found to identify patients
evolved into definite SSc during follow-up with a 30 %
sensitivity and 86 % specificity (AUC 0.69).
Discussion
CXCL4 is a 7.8-kDa protein that comprises from 2 to 3 %
of the protein content of activated platelets and is consid-
ered one of the most anti-angiogenic chemokines [13].
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In their pivotal paper, van Bon et al. [9] reported a
correlation between CXCL4 levels and the extent of skin
fibrosis in patients affected by SSc. Moreover, they
found higher CXCL4 levels were associated with lung
fibrosis and pulmonary arterial hypertension and resulted
to be predictive of faster decline in DLCO, faster pro-
gression of skin fibrosis and higher incidence of lung
fibrosis in 79 SSc patients followed up for 18 months.
These authors also mentioned increased CXCL4 values
in ‘‘very early’’ SSc, but did not investigate either the
presence of associations or the prognostic value of the
finding.
We undertook the present study in order to address these
aspects. Unlike van Bon et al. [1], who assessed CXCL4
levels in plasma, we investigated the chemokine levels in
the serum, because increased levels of chemokine in
plasma can depend on its release from platelets [14]. Since
platelet activation occurs in SSc, we opted to assess
CXCL4 levels in the serum in order to better evaluate the
Table 1 Demographic, serological, capillaroscopic features and functional abnormalities indicative of preclinical internal organ involvement in
45 patients divided into 3 subsets
Features Whole cohort Subset I Subset II Subset III
Sex (F/M) 43/2 27/1 12/1 4/0
Age (years: median; range) 42 (37–48.5) 41 (34–45) 42 (39.2–50.2) 56 (47–62)
Disease duration from RP (years: median; range) 2 (1–5.25) 3 (2–6) 2 (1–4.2) 2.5 (1.5–17)
Marker autoantibody positivity 41 28 13 0
Anti-centromere 30 (66.6 %) 21/28 (75 %) 9/13 (69.23 %)
Anti-DNA topoisomerase I 10/45 (22.2 %) 6/28 (21.4 %) 4/13 (30.7 %)
Anti-PM-Scl 1/45 (2.2 %) 1/28 (3.5 %)
Capillaroscopic alterations 32 28 0 4
Megacapillaries 28/32 (87.5 %) 24/28 (85.7 %) 4/4 (100 %)
Avascular areas 4/32 (12.5 %) 4/28 (14.2 %) 0
DLCO\80 % of the predicted value 17/45 (37.8 %) 8/28 (28.5 %) 6/13 (46.1 %) 3/4 (75 %)
E/A\ 1a 0 0 0 0
Low esophageal sphincter pressure\15 mm Hg 8/29 (27.6 %) 5/18 (27.7 %) 2/9 (22.2 %) 1/2 (50 %)
RP Raynaud’s phenomenon, DLCO diffusing lung capacity for carbon monoxide, E/A early/atrial ratio
a In patients aged\50 years, with an arterial blood pressure\130/85 mmHg
Fig. 1 CXCL4 levels in healthy controls (HC), in the whole cohort
(WC) of UCTD-SSc-risk patients
Fig. 2 Receiver operator curve showing the relationship between
baseline serum CXCL4 and evolution into definite SSc
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amount of the circulating chemokine probably secreted by
plasmocytoid dendritic cells, which constitute its main
source in SSc [9].
Despite the different origin of the samples used, we
confirm the original report by van Bon et al. [9] that
CXCL4 levels are higher in UCTD-risk-SSc patients, who
had been referred by them as ‘‘very early SSc.’’
We investigated the presence of associations between
CXCL4 levels and disease duration from the onset of RP,
disease subsetting, autoantibody specificity, preclinical
internal organ involvement as well as the value as a
prognostic marker of evolution into definite SSc.
We found that CXCL4 levels are almost significantly
higher in patients lacking microcirculatory abnormalities as
detected by nailfold videocapillaroscopy. These associa-
tions should be evaluated further in a larger series of
patients also assessed for other factors influencing angio-
genesis in SSc, for example vascular endothelial growth
factor (VEGF). Notably, megacapillaries, which were the
only microvascular abnormality in most our patients (28/
45), may represent a compensatory mechanism, promoted
by VEGF that might be inhibited by CXCL4 [15].
As far as CXCL4 prognostic value is concerned, ROC
analysis pointed out a significant specificity, suggesting a
potential role of its evaluation in the assessment of the
UCTD-risk-SSc patient at baseline. Such a role is, how-
ever, challenged by its low sensitivity.
The prognostic value of CXCL4 in definite SSc pointed
out by van Bon et al. [9] has been recently challenged by
Volkmann et al. [16] who investigated patients enrolled
into Scleroderma Lung Study 2. This aspect, therefore, also
awaits to be clarified in definite SSc.
In conclusion, we confirmed that increased CXCL4
levels are detected in UCTD-SSc-risk patients. Further
studies on a larger, possibly multicentric series, are needed
to assess the value of CXCL4 and other biomarkers in
predicting the evolution in UCTD-SSc-risk. At present,
predicting prognosis in SSc relies on the definition of the
subset [3, 4] and the presence of preclinical organ
involvement at admission [4].
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